Depypere, Herman;
Vergallo, Andrea;
Lemercier, Pablo;
Lista, Simone;
Benedet, Andrea;
Ashton, Nicholas;
Cavedo, Enrica;
... Neurodegeneration Precision Medicine Initiative (NPMI), (NPMI); + view all
(2023)
Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease.
Alzheimer's & Dementia
, 19
(4)
pp. 1320-1330.
10.1002/alz.12759.
Preview |
Text
Menopause hormone therapy significantly alters pathophysiological biomarkers.pdf - Published Version Download (647kB) | Preview |
Abstract
INTRODUCTION: This increasing body of literature indicates that menopause hormonal replacement therapy (MHT) may substantially mitigate the risk of developing late-life cognitive decline due to progressive Alzheimer's disease (AD) pathophysiology. For the first time, we investigated the question whether MHT impacts AD biomarker-informed pathophysiological dynamics in de-novo diagnosed menopausal women. METHODS: We analyzed baseline and longitudinal differences between MHT-taking and -not women in terms of concentrations of core pathophysiological AD plasma biomarkers, validated in symptomatic and cognitively healthy individuals, including biomarkers of (1) the amyloid-β (Aβ) pathway, (2) tau pathophysiology, (3) neuronal loss, and (4) axonal damage and neurodegeneration. RESULTS: We report a prominent and significant treatment response at the Aβ pathway biomarker level. Women at genetic risk for AD (APOE e4 allele carriers) have particularly shown favorable results from treatment. DISCUSSION: To our knowledge, we present first prospective clinical evidence on effects of MHT on AD pathophysiology during menopause.
| Type: | Article |
|---|---|
| Title: | Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/alz.12759 |
| Publisher version: | https://doi.org/10.1002/alz.12759 |
| Language: | English |
| Additional information: | © 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Keywords: | Neurodegeneration Precision Medicine Initiative (NPMI) |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10159421 |
Archive Staff Only
 |
View Item |
